Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Soluble thrombomodulin levels in plasma of multiple sclerosis patients and their implication.
Pathological mechanisms in progressive multiple sclerosis.
Long-term daclizumab therapy in relapsing-remitting multiple sclerosis.
Claudin-1 induced sealing of blood-brain barrier tight junctions ameliorates chronic experimental autoimmune encephalomyelitis.
Stem cells in autoimmune diseases: Implications for pathogenesis and future trends in therapy.
Population pharmacokinetics of daclizumab high-yield process in healthy volunteers: integrated analysis of intravenous and subcutaneous, single- and multiple-dose administration.
Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorder Patients in Turkish Cohort: Demographic, Clinical, and Laboratory Features.
Intellectual enrichment lessens the effect of brain atrophy on learning and memory in multiple sclerosis.
Cognitive impairment in multiple sclerosis.
Factors associated with the time to next attack in neuromyelitis optica: accelerated failure time models with random effects.
Title: Pharmacokinetics and Pharmacodynamics of Peginterferon Beta-1a in Patients with Relapsing-Remitting Multiple Sclerosis in the Randomised ADVANCE Study.
Decreased microglial activation in MS patients treated with glatiramer acetate.
Lesion morphology at 7 Tesla MRI differentiates Susac syndrome from multiple sclerosis.
Management of Fulminant Multiple Sclerosis With Rituximab: A Case Report.
Daclizumab for relapsing remitting multiple sclerosis.
Tumefactive Multiple Sclerosis presenting as Acute Ischemic Stroke.
Rituximab in paediatric onset multiple sclerosis: a case series.
FDA denies Teva Copaxone generic trials petition
Lamotrigine for neuroprotection in secondary progressive multiple sclerosis: a randomised, double-blind, placebo-controlled, parallel-group trial.
Discontinuation of Disease-Modifying Treatment for Multiple Sclerosis
The prediction of human response to ONO-4641, a sphingosine 1-phosphate receptor modulator, from preclinical data based on pharmacokinetic-pharmacodynamic modeling.
Cladribine
Safety and tolerability of cladribine tablets in multiple sclerosis: the CLARITY (CLAdRIbine Tablets treating multiple sclerosis orallY) study.
lambda-Interferons and the single nucleotide polymorphisms: A milestone to tailor-made therapy for chronic hepatitis C.
Receptos initiates clinical trials for S1P1 agonist program, aimed at multiple sclerosis

Pages